New Onset Scleroderma in Elderly Males-A Case Series-Based Review of the Literature

老年男性新发硬皮病——基于病例系列的文献综述

阅读:1

Abstract

Scleroderma is an autoimmune disease traditionally affecting middle-aged females. Its occurrence in elderly males is uncommon and often associated with severe manifestations such as interstitial lung disease, cardiac involvement, and renal crises. This study aims to highlight the clinical features, diagnostic challenges, and outcomes of new-onset scleroderma in elderly males. In this case series-based review of new-onset scleroderma among elderly males, we describe the clinical manifestations and outcomes of 4 patients under our care, and review the epidemiology, clinical presentations, and prognosis of this specific group. The case series included 4 men aged 68 to 87 years. All patients presented with various atypical presentations and organ involvement. Laboratory tests revealed high titers of anti-nuclear antibodies in all patients. Either anti-RNA polymerase III or anti-SCL70 antibodies were positive in 3 patients, with the fourth positive with anti-Ro52 antibodies. Imaging and biopsies confirmed organ involvement in 3, with the fourth lost to follow-up. The time to diagnosis ranged from months to years. Two patients died from sudden cardiac death, reflecting a poor prognosis in this subpopulation. Classically, scleroderma is considered a disease affecting middle-aged women. In this case-based review, we highlight a rare and presumably underdiagnosed cohort of scleroderma patients. Multisystemic conditions usually attributed to old age may reflect clinical manifestations of scleroderma. This case series-based highlights what may be the tip of an iceberg regarding elderly males with scleroderma; the review underscores the necessity for heightened clinical vigilance and tailored management strategies for elderly males with suspected scleroderma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。